AstraZeneca (AZN) said Friday that results from its phase 3 trial showed its bladder cancer treatment candidate, Imfinzi, improved event-free survival and overall survival in patients with muscle-invasive bladder cancer.
The benefits were observed regardless of whether patients achieved a pathologic complete response, according to the company.
Patients in the study were treated with four cycles of Imfinzi combined with chemotherapy before undergoing bladder removal surgery, followed by eight cycles of Imfinzi monotherapy.
The analysis showed that Imfinzi improved both event-free and overall survival compared to chemotherapy and surgery alone, benefiting patients regardless of whether they achieved a pathologic complete response.
The regimen reduced the risk of disease progression, recurrence, failure to undergo surgery, and death, as well as the risk of death from bladder cancer, according to the company.
AstraZeneca said the treatment with the trial met the primary endpoint of event-free survival and the secondary endpoint of overall survival.
Price: 74.15, Change: -0.30, Percent Change: -0.40
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。